STAT+: Seven burning questions about the FDA’s post-Overton future

STAT+: Seven burning questions about the FDA’s post-Overton future

WASHINGTON — The White House pulled its nomination of Heidi Overton for commissioner of the Food and Drug Administration on Tuesday evening, startling senators on the health committee and introducing new questions about the future of the FDA. The decision is a blow to an agency that thrives on stability and has been without a permanent head since May, though it was beginning to enjoy a period of relative normalcy under acting commissioner Kyle Diamantas. The FDA is on its third leader of this Trump administration, and whoever replaces Overton as nominee could be the fourth. The FDA is facing a number of challenges. The user fees that fund the agency’s drug reviews need to be reauthorized, a process that may be complicated by Democrats’ sweeping midterm election wins. And leaders are confronting the rise of AI in scientific research and working to aid the Trump administration’s push to compete with China’s biotech industry. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Original Source

Read the full article at Statnews →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.